Translating Mathematical Modeling of Tumor Growth Patterns into Novel Therapeutic Approaches for Breast Cancer
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
In breast cancer, mortality is driven by the metastatic process, whereby some cancer cells leave their primary site of origin and travel to distant vital organs. Despite improved screening and therapies to treat breast cancers, metastasis continues to undermine these advances. The pervasive albatross of metastasis necessitates improved prevention and treatment of metastasis. To this end, clinicians routinely employ post-operative or adjuvant therapy to decrease the risk of future metastasis and improve the chance for cure. This article evaluates the limitations of breast cancer therapies within the context of growth curves, and in doing so, provides new insight into the metastatic process as well as more effective means for therapeutic delivery. Two critical developments evolve from this mathematical analysis: first, the use of dose dense chemotherapy to improve survival among breast cancer patients; and second, the theory of self-seeding, which fundamentally changes our understanding of metastasis and the trajectory of drug development.
Supplementary Material (0)
- Stewart BW KP. World Cancer Report. In IARC Press. 2003.
- Skipper HE, Schabel Jr FM, Wilcox WS, Skipper HE, Schabel Jr FM, Wilcox WS. Experimental evaluation of potential anticancer agents. Xiii. On the criteria and kinetics associated with “Curability” of experimental leukemia. Cancer Chemother Rep. 1964;35:1–111.
- Skipper HE. Laboratory models: some historical perspective. Cancer Treat Rep. 1986;70:3–7.
- Simpson-Herren L, Lloyd HH. Kinetic parameters and growth curves for experimental tumor systems. Cancer Chemother Rep. 1970;54:143–74.
- Norton L. Cancer stem cells, self-seeding, and decremented exponential growth: theoretical and clinical implications. Breast Dis. 2008;29:27–36.
- Demicheli R, Terenziani M, Valagussa P, et al. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst. 1994;86:45–8. CrossRef
- Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307–17.
- Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Phil Trans Roy Soc London. 1832;123:513–85.
- Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48:7067–71.
- Norton L, Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst. 1977;58:1735–41.
- Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol. 1985;12:231–49.
- Zsebo KM, Cohen AM, Murdock DC, et al. Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology. 1986;172:175–84. CrossRef
- Morris PG, McArthur HL, Hudis C, Norton L. Dose-dense chemotherapy for breast cancer: what does the future hold? Future Oncol. 2010;6:951–65. CrossRef
- Hudis C, Fornier M, Riccio L, et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol. 1999;17:1118.
- Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol. 1999;17:93–100.
- Fornier MN, Seidman AD, Theodoulou M, et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res. 2001;7:3934–41.
- Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9. CrossRef
- Hudis C, Citron ML, Berry D. Five year follow-up of INT C9741: dose dense chemotherapy is safe and effective. Breast Cancer Res. 2005;94 suppl 91:S20.
- Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005;97:1724–33. CrossRef
- Burnell M, Levine MN, Chapman JA, et al. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2009;28:77–82. CrossRef
- Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010;28:2874–80. CrossRef
- Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–71. CrossRef
- Hudis C, Modi S. Preoperative chemotherapy for breast cancer: miracle or mirage? JAMA. 2007;298:2665–7. CrossRef
- Untch M, Mobus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27:2938–45. CrossRef
- Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol. 2010;28:3407–10. CrossRef
- Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84. CrossRef
- Slamon D, Eiermann W, Robert N et al. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC?T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC?TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. San Antonio Breast Cancer Symposium 2009; Abstract 62.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72. CrossRef
- Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–20. CrossRef
- Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol. 2008;26:1216–22. CrossRef
- Morris PG, Dickler M, McArthur HL, et al. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009;27:6117–23. CrossRef
- Kummel S, Krocker J, Kohls A, et al. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial. Crit Rev Oncol Hematol. 2006;58:166–75. CrossRef
- Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat. 2009;117:205–10. CrossRef
- Drullinsky P, Fornier MN, Sugarman S et al. Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10–11-day dosing intervals for women with early-stage breast cancer. Proc Am Soc Clin Oncol 2009; Abstract 590.
- Fornier MN, Seidman AD, Lake D, et al. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clin Cancer Res. 2007;13:223–7. CrossRef
- Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med. 2006;12:875–8. CrossRef
- Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–26. CrossRef
- Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9:302–12. CrossRef
- Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126:589–98. CrossRef
- Doron Y, Gruszkiewicz J. Metastasis of invasive carcinoma of the breast to an extradural meningioma of the cranial vault. Cancer. 1987;60:1081–4. CrossRef
- Bernstein RA, Grumet KA, Wetzel N. Metastasis of prostatic carcinoma to intracranial meningioma. Case report. J Neurosurg. 1983;58:774–7. CrossRef
- Sella A, Ro JY. Renal cell cancer: best recipient of tumor-to-tumor metastasis. Urology. 1987;30:35–8. CrossRef
- Cenkowski M, Gibson IW, Lategan B, Czaykowski PM. Tumor-to-tumor metastasis: report of a case of renal cell carcinoma metastasizing to a pancreatic endocrine neoplasm. J Clin Oncol. 2011;29:e303–4. CrossRef
- Newton PK, Mason J, Bethel K, et al. A stochastic Markov chain model to describe lung cancer growth and metastasis. PLoS One. 2012;7:e34637. CrossRef
- Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1–19. CrossRef
- Irving A. Results of treating 1,178 patients with breast cancer by radical mastectomy and postoperative irradiation where metastases to axillary lymph nodes occurred. J Surg Oncol. 1979;12:137–53. CrossRef
- Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240:306–12. CrossRef
- Shapiro DM, Fugmann RA. A role for chemotherapy as an adjunct to surgery. Cancer Res. 1957;17:1098–101.
- Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer. 1977;40:574–87. CrossRef
- Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93. CrossRef
- Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75. CrossRef
- Wo JY, Chen K, Neville BA et al. Effect of Very Small Tumor Size on Cancer-Specific Mortality in Node-Positive Breast Cancer. J Clin Oncol 2011.
- Hernandez-Aya LF, Chavez-Macgregor M, Lei X et al. Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. J Clin Oncol 2011.
- Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24. CrossRef
- Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–9. CrossRef
- Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67–78. CrossRef
- Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359–77. CrossRef
- Group ECO. A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer E2108. In. 2011.
- Neuman HB, Morrogh M, Gonen M, et al. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer. 2010;116:1226–33. CrossRef
- Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009;115:7–12. CrossRef
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26. CrossRef
- van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. CrossRef
- Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800. CrossRef
- Perry MC. The chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
- Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8:369–77.
About this Article
- Translating Mathematical Modeling of Tumor Growth Patterns into Novel Therapeutic Approaches for Breast Cancer
Journal of Mammary Gland Biology and Neoplasia
Volume 17, Issue 3-4 , pp 241-249
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Norton-Simon hypothesis
- Dose-dense chemotherapy
- Breast cancer
- Industry Sectors